BioArray Solutions
With FDA Approval in Hand, Immucor Sets out to Convert Blood Transfusion Labs to HEA Array Test
Premium
NEW YORK (GenomeWeb) — Immucor believes the recent US regulatory approval of its microarray-based PreciseType Human Erythrocyte Antigen test for determining blood compatibility will encourage more customers to introduce the assay in a clinical setting.
IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep: Jul 13, 2011
Premium
US patents awarded to Nishikawa Rubber, Virco, Bioarray Solutions, Aisin Seiki, Riken, Abacus Diagnostica, Sigma-Aldrich, Illumina, LLNL, OncoMedX, Brandeis University, and Epigenomics.
IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep: Jun 28, 2011
Premium
BioArray Solutions, DuPont, and Becton Dickinson awarded US patents.
CEO Gioacchino De Chirico said the postponement will have no impact on the timing of Immucor's plan to submit the system to the US Food and Drug Administration for clearance.
While the assay has been available for research use in Europe, the company believes its certification as an in vitro diagnostic will allow more users in blood banks, clinical laboratories, and blood donor centers to adopt the technology.
Sep 1, 2009